Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FBXO48 is a member of the F-box protein family and functions as an E3 ubiquitin ligase subunit within the SCF complex. Its primary known role is to recognize and target phosphorylated AMPKα for polyubiquitylation and subsequent proteasomal degradation. This positions FBXO48 as a negative regulator of cellular energy homeostasis, controlling the cellular signaling cascade that governs mitochondrial fission, autophagy, and insulin sensitivity. Inhibition of FBXO48, for example with small molecules such as BC1618, can prevent pAMPKα degradation, enhance AMPK-mediated metabolic effects, and improve hepatic insulin sensitivity, suggesting promise for metabolic disease therapy. FBXO48 is genomically localized to 2p13.3, a region connected to Parkinson's disease in genetic studies, though direct disease–causing mutations have not been established.
Inhibition of FBXO48 prevents ubiquitylation and degradation of pAMPKα, resulting in maintained AMPK signaling and downstream metabolic effects
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on F-box protein 48 (FBXO48).